News From:
                                           Redington, Inc.
Delcath Systems, Inc.                      49 Richmondville, Westport, CT  06880

================================================================================
Release Date: IMMEDIATE

                                                                      Exhibit 99
                                                                      ----------
Contact:
        M.S. Koly                              Thomas Redington
        Chief Executive Officer                Redington, Inc
        Delcath Systems, Inc.                  203/222-7399
        203/323-8668                           212/926-1733
        www.delcath.com                        www.redingtoninc.com
        ---------------                        --------------------


                DELCATH ANNOUNCES A PUBLIC OFFERING OF SECURITIES
                -------------------------------------------------


           STAMFORD, CT DEC 9 - Delcath Systems, Inc. (Nasdaq: DCTH)
       announced today that it has filed a registration statement with
       the Securities and Exchange Commission for an underwritten public
       offering of securities in the form of units. Each unit will
       consist of shares of common stock and warrants to purchase shares
       of common stock. Delcath anticipates that, if the offering is
       completed, it will use the net proceeds it receives for working
       capital to fund human clinical trials and pay other associated
       costs in connection with obtaining pre-marketing approval of the
       Delcath system from the U.S. Food and Drug Administration.
       Roan/Meyers Associates, L.P. will represent the underwriters in
       connection with the anticipated offering.
           Delcath is a development stage company that has developed a
       system, the Delcath system, which is designed to administer high
       doses of chemotherapy to the liver for treatment of liver cancer.
       The Delcath system is not currently approved for marketing by the
       FDA, and it cannot be marketed in the United States without FDA
       pre-marketing approval.
           The registration statement has been filed with the Securities
       and Exchange Commission but has not yet become effective. The
       units may not be sold nor may offers to buy the units be accepted
       prior to the time the registration statement becomes effective.
       This release shall not constitute an offer to sell or the
       solicitation of an offer to buy nor shall there be any sale of
       these securities in any state in which such offer, solicitation or
       sale would be unlawful prior to registration or qualification
       under the securities laws of any such state.
           Any statements released by Delcath that are forward-looking
       are made pursuant to the safe harbor provisions of the Private
       Securities Litigation Reform Act of 1995. Terms such as
       "anticipates," "expects," words of similar import and variations
       on such words are intended to identify forward-looking statements.
       Investors are cautioned that forward-looking statements
       necessarily involve risks and uncertainties which are difficult to
       predict and actual outcomes may vary materially from what is
       expressed or forecasted in such forward-looking statements.
           When available, copies of the preliminary prospectus filed as
       part of the registration statement may be obtained without charge,
       by directing a

                                     -more-



       request to Delcath Systems, Inc., 1100 Summer Street, Stamford,
       Connecticut 06905,  Attention:  M. S. Koly.
           Delcath, a development-stage company, is in the business of
       developing and marketing a proprietary drug delivery system
       capable of introducing, and removing, high-dose chemotherapy
       agents to a diseased organ system while greatly inhibiting their
       entry into the general circulatory system.

                        #            #             #

           This release contains "FORWARD-LOOKING STATEMENTS" BASED ON
       CURRENT EXPECTATIONS BUT INVOLVING KNOWN AND UNKNOWN RISKS AND
       UNCERTAINTIES. ACTUAL RESULTS OR ACHIEVEMENTS MAY BE MATERIALLY
       DIFFERENT FROM THOSE EXPRESSED OR IMPLIED. DELCATH PLANS AND
       OBJECTIVES ARE BASED ON ASSUMPTIONS INVOLVING JUDGMENTS WITH
       RESPECT TO FUTURE ECONOMIC, COMPETITIVE AND MARKET CONDITIONS, ITS
       ABILITY TO CONSUMMATE, AND THE TIMING OF, ACQUISITIONS AND FUTURE
       BUSINESS DECISIONS, ALL OF WHICH ARE DIFFICULT OR IMPOSSIBLE TO
       PREDICT ACCURATELY AND MANY OF WHICH ARE BEYOND ITS CONTROL.
       THEREFORE, THERE CAN BE NO ASSURANCE THAN ANY FORWARD-LOOKING
       STATEMENT WILL PROVE TO BE ACCURATE.

       12/9/02